$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415031588 Filed on May 15, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q2
Revenue	$320.0K	$349.0K	$210.0K
YoY Change	52.38%		-66.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.450M	$1.220M	$1.950M
YoY Change	-25.64%	28.42%	105.26%
% of Gross Profit
Research & Development	$760.0K	$815.0K	-$590.0K
YoY Change	-228.81%	137.61%	-160.82%
% of Gross Profit
Depreciation & Amortization	$100.0K	$11.00K	$90.00K
YoY Change	11.11%	-87.78%	0.0%
% of Gross Profit
Operating Expenses	$2.210M	$2.037M	$1.360M
YoY Change	62.5%	57.42%	-29.17%
Operating Profit		-$1.688M
YoY Change		30.45%
Interest Expense	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$10.00K	$11.00K	$10.00K
YoY Change	0.0%	-26.67%	0.0%
Pretax Income	-$1.890M	-$1.680M	-$1.140M
YoY Change	65.79%	31.25%	-13.64%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.890M	-$1.677M	-$1.140M
YoY Change	65.79%	31.12%	-13.64%
Net Earnings / Revenue	-590.63%	-480.52%	-542.86%
Basic Earnings Per Share
Diluted Earnings Per Share	-$248.0K	-$230.1K	-$173.8K
COMMON SHARES
Basic Shares Outstanding	76.76M shares		65.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.490M	$8.080M	$3.590M
YoY Change	164.35%	86.61%	-18.59%
Cash & Equivalents	$9.494M	$8.080M	$3.590M
Short-Term Investments
Other Short-Term Assets	$17.00K	$300.0K	$8.000K
YoY Change	112.5%	57.89%	-74.19%
Inventory
Prepaid Expenses
Receivables	$445.0K	$341.0K	$205.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.12M	$9.044M	$3.913M
YoY Change	158.65%	63.49%	-41.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.00K	$14.00K	$6.000K
YoY Change	116.67%	100.0%	0.0%
Goodwill
YoY Change
Intangibles	$2.360M	$2.388M	$2.575M
YoY Change	-8.35%	-10.73%	-5.09%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.373M	$2.402M	$2.581M
YoY Change	-8.06%	-10.44%	-5.08%
TOTAL ASSETS
Total Short-Term Assets	$10.12M	$9.044M	$3.913M
Total Long-Term Assets	$2.373M	$2.402M	$2.581M
Total Assets	$12.49M	$11.45M	$6.494M
YoY Change	92.39%	39.35%	-30.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.104M	$815.0K	$297.0K
YoY Change	271.72%	-27.1%	-87.63%
Accrued Expenses	$159.0K	$405.0K	$98.00K
YoY Change	62.24%	326.32%	-94.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.263M	$1.250M	$395.0K
YoY Change	219.75%	3.05%	-90.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.263M	$1.250M	$395.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.263M	$1.254M	$395.0K
YoY Change	219.75%	3.64%	-90.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.83M	-$45.94M	-$41.20M
YoY Change	16.08%	14.68%	9.77%
Common Stock	$59.08M	$56.16M	$47.30M
YoY Change	24.91%	19.33%	11.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.23M	$10.19M	$6.099M
YoY Change
Total Liabilities & Shareholders Equity	$12.49M	$11.45M	$6.494M
YoY Change	92.39%	39.35%	-30.58%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q2
OPERATING ACTIVITIES
Net Income	-$1.890M	-$1.677M	-$1.140M
YoY Change	65.79%	31.12%	-13.64%
Depreciation, Depletion And Amortization	$100.0K	$11.00K	$90.00K
YoY Change	11.11%	-87.78%	0.0%
Cash From Operating Activities	-$1.210M	-$1.330M	-$690.0K
YoY Change	75.36%	9.02%	-24.18%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	-$50.00K	-$60.00K
YoY Change	16.67%	-58.33%	50.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$70.00K	-$50.00K	-$60.00K
YoY Change	16.67%	-58.33%	50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.700M	2.090M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-1.210M	-1.330M	-690.0K
Cash From Investing Activities	-70.00K	-50.00K	-60.00K
Cash From Financing Activities	2.700M	2.090M	0.000
Net Change In Cash	1.420M	710.0K	-750.0K
YoY Change	-289.33%	-152.99%	-126.04%
FREE CASH FLOW
Cash From Operating Activities	-$1.210M	-$1.330M	-$690.0K
Capital Expenditures	-$70.00K	-$50.00K	-$60.00K
Free Cash Flow	-$1.140M	-$1.280M	-$630.0K
YoY Change	80.95%	16.36%	-27.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2014Q2	us-gaap	Liabilities Liabilities	395000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	76755410	shares
	dei	Trading Symbol TradingSymbol	IBIO
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	815000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1480000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	815000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8080000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3590000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	341000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	205000	USD
CY2015Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	325000	USD
CY2014Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	298000	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	118000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	9044000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	3913000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6000	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2388000	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2575000	USD
CY2015Q1	us-gaap	Assets Assets	11446000	USD
CY2014Q2	us-gaap	Assets Assets	6494000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	297000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	405000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	98000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	1254000	USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	74000	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	66000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	56086000	USD
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	47235000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45942000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41202000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	10192000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	6099000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11446000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6494000	USD
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74070958	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Use of Estimates</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies, and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Reclassifications</i> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: #231f20" align="justify">Certain amounts in the March 31, 2014 statement of cash flows were reclassified to conform to the current period presentation. In 2014, the changes in operating assets and liabilities were reported as one line item. In 2015, such 2014 changes were reported by account.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	102000	USD
CY2014Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	38000	USD
CY2015Q1	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2014Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	951000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1222000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1677000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	15000000	shares
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1636000	shares
CY2014Q3	ibio	Floor Price Of Common Stock FloorPriceOfCommonStock	0.20
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1279000	USD
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65642095	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74070958	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65642095	shares
CY2015Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5218000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5168000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2830000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2593000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2388000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2575000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	91000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	88000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	266000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	266000	USD
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8769911	shares
	ibio	Class Of Warrants Or Rights Expired ClassOfWarrantsOrRightsExpired	425587	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6633324	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.38
	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	0.66
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2524000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4740000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65642000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72989000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62080000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69913000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	8800000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	9700000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8800000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	6600000	shares
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	325000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	224000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	690000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1179000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	349000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1535000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	343000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2731000	USD
CY2014Q1	ibio	Research And Development Expense Effect Of Settlement Agreement ResearchAndDevelopmentExpenseEffectOfSettlementAgreement	0	USD
CY2015Q1	ibio	Research And Development Expense Effect Of Settlement Agreement ResearchAndDevelopmentExpenseEffectOfSettlementAgreement	0	USD
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	688000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	ibio	Stock Issued During Period Value Capital Contribution And Commitment Fee StockIssuedDuringPeriodValueCapitalContributionAndCommitmentFee	1000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	30000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2950000	USD
	ibio	Research And Development Expense Effect Of Settlement Agreement ResearchAndDevelopmentExpenseEffectOfSettlementAgreement	-1041000	USD
	ibio	Research And Development Expense Effect Of Settlement Agreement ResearchAndDevelopmentExpenseEffectOfSettlementAgreement	0	USD
CY2014Q1	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	9000	USD
CY2015Q1	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	9000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	34000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	24000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	165000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3574000	USD
CY2014Q1	ibio	General And Administrative Expense Effect Of Settlement Agreement GeneralAndAdministrativeExpenseEffectOfSettlementAgreement	0	USD
CY2015Q1	ibio	General And Administrative Expense Effect Of Settlement Agreement GeneralAndAdministrativeExpenseEffectOfSettlementAgreement	0	USD
	ibio	General And Administrative Expense Effect Of Settlement Agreement GeneralAndAdministrativeExpenseEffectOfSettlementAgreement	-700000	USD
	ibio	General And Administrative Expense Effect Of Settlement Agreement GeneralAndAdministrativeExpenseEffectOfSettlementAgreement	0	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	1294000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	2037000	USD
	us-gaap	Operating Expenses OperatingExpenses	2689000	USD
	us-gaap	Operating Expenses OperatingExpenses	6305000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1294000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1688000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2689000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4770000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2014Q1	ibio	Interest Expense Effect Of Settlement Agreement InterestExpenseEffectOfSettlementAgreement	0	USD
CY2015Q1	ibio	Interest Expense Effect Of Settlement Agreement InterestExpenseEffectOfSettlementAgreement	0	USD
	ibio	Interest Expense Effect Of Settlement Agreement InterestExpenseEffectOfSettlementAgreement	-122000	USD
	ibio	Interest Expense Effect Of Settlement Agreement InterestExpenseEffectOfSettlementAgreement	0	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1279000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-1677000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2524000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4740000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-12000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-26000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1279000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1689000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2524000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4766000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5300000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.43
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1400000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription	Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million
CY2015Q1	us-gaap	Contractual Obligation ContractualObligation	3000000	USD
CY2014Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	124000	USD
CY2015Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	258000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	430000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	738000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	690000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-152000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	480000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7302000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3551000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8169000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-9000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-81000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	835000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	690000	USD
	us-gaap	Depreciation Depreciation	2000	USD
	us-gaap	Depreciation Depreciation	3000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	135000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	0	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	325000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	181000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-133000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	517000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-39000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	306000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3432000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3518000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	196000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	137000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4490000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4414000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4333000	USD
	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	12000	USD
	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	0	USD
	ibio	Unpaid Intangible Assets Included In Accrued Expenses UnpaidIntangibleAssetsIncludedInAccruedExpenses	20000	USD
	ibio	Unpaid Intangible Assets Included In Accrued Expenses UnpaidIntangibleAssetsIncludedInAccruedExpenses	12000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">Nature of Business</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies - the iBioLaunch platform for vaccines and therapeutic proteins and the iBioModulator platform for vaccine enhancement and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods, and reduced production time, capital and operating costs for biopharmaceuticals. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company has two wholly-owned subsidiaries, iBioDefense Biologics LLC (“iBioDefense”), a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology, and iBio Peptide Therapeutics LLC, a Delaware limited liability company formed in November 2013. Both of these subsidiaries are dormant. Additionally the Company has a 99% interest in a subsidiary organized in Brazil, iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”), to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/FioCruz (“FioCruz”) beyond the current Yellow Fever Vaccine program (see Note 6) and development of biosimilar products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	ibio	Effect Of Settlement Agreement EffectOfSettlementAgreement	1863000	USD
	ibio	Effect Of Settlement Agreement EffectOfSettlementAgreement	0	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-47000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3100000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	867000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	29000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	ibio	Expiration Of Warrants ExpirationOfWarrants	71000	USD
	ibio	Expiration Of Warrants ExpirationOfWarrants	0	USD
	ibio	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	1711000	shares
	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	500000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.87
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1201000	USD
	ibio	Common Stock Issued For Warrant Exercises Value CommonStockIssuedForWarrantExercisesValue	867000	USD
CY2015Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-17000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7301000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q1	us-gaap	Deferred Revenue DeferredRevenue	34000	USD
CY2014Q2	us-gaap	Deferred Revenue DeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	34000	USD
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0.44	shares

Files In Submission

Name	View Source	Status
0001144204-15-031588-index-headers.html	Edgar Link	pending
0001144204-15-031588-index.html	Edgar Link	pending
0001144204-15-031588.txt	Edgar Link	pending
0001144204-15-031588-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ibio-20150331.xml	Edgar Link	completed
ibio-20150331.xsd	Edgar Link	pending
ibio-20150331_cal.xml	Edgar Link	unprocessable
ibio-20150331_def.xml	Edgar Link	unprocessable
ibio-20150331_lab.xml	Edgar Link	unprocessable
ibio-20150331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v409249_10q.htm	Edgar Link	pending
v409249_ex10-1.htm	Edgar Link	pending
v409249_ex31-1.htm	Edgar Link	pending
v409249_ex31-2.htm	Edgar Link	pending
v409249_ex32-1.htm	Edgar Link	pending
v409249_ex32-2.htm	Edgar Link	pending
v409249_ex4-2.htm	Edgar Link	pending
v409249_ex5-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2015 Q2 Form 10-Q Financial Statement

#000114420415031588 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2015 Q2 Form 10-Q Financial Statement

#000114420415031588 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio